AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Recruiting

Phase 2

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell DepletionAlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Sponsor:

Mitchell Cairo

Code:

NCT04099966

Conditions

Acute Leukemia

Severe Aplastic Anemia

Non-hodgkin Lymphoma

Hodgkin Lymphoma

Kostmann

Eligibility Criteria

Sex: All

Age: 1 - 30

Healthy Volunteers: Not accepted

Interventions

alpha beta depletion

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-01. This information was provided to ClinicalTrials.gov by Mitchell Cairo on 2023-10-26.